ClinicalTrials.gov
public full text
Public Domain
Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
This study will evaluate the efficacy and safety of irinotecan liposome(II) in combination with Ivonescimab as second line treatment for SCLC.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities#1102009
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients#1171119
- Ivonescimab combined with chemotherapy for the treatment of metastatic cervical cancer: A case report and literature review#125743
- Targeting the LIPH-CD36 axis potentiates CDK4/6 inhibition in ER+ breast cancer#475685
- Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer#426778
Record · ID 883954
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive